INTERLEUKIN-17A IS A NEW TARGET OF ANTICYTOKINE THERAPY FOR ANKYLOSING SPONDYLITIS
Therapy for ankylosing spondylitis (AS) is a challenge for a physician, primarily because of a small number of therapeutic alternatives. Interleukin-17 (IL17), a novel promising therapeutic target, has been recently disclosed. The first representative of the new group of drugs – anti-IL17A monoclon...
| Egile nagusia: | |
|---|---|
| Formatua: | Artikulua |
| Hizkuntza: | Russian |
| Argitaratua: |
IMA PRESS LLC
2016-09-01
|
| Saila: | Научно-практическая ревматология |
| Gaiak: | |
| Sarrera elektronikoa: | https://rsp.mediar-press.net/rsp/article/view/2255 |